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The endotheliotropism of equine herpesvirus-1 (EHV-1) leads to encephalomyelitis secondary
to vasculitis and thrombosis in the infected horse central nervous system (CNS). To identify
the host factors involved in EHV-1 infection of CNS endothelial cells, we performed functional
cloning using an equine brain microvascular endothelial cell cDNA library. Exogenous expres-
sion of equine major histocompatibility complex (MHC) class I heavy chain genes conferred
susceptibility to EHV-1 infection in mouse NIH3T3 cells, which are not naturally susceptible
to EHV-1 infection. Equine MHC class I molecules bound to EHV-1 glycoprotein D (gD),
and both anti-gD antibodies and a soluble form of gD blocked viral entry into NIH3T3 cells
stably expressing the equine MHC class I heavy chain gene (3T3-A68 cells). Treatment with an
anti-equine MHC class I monoclonal antibody blocked EHV-1 entry into 3T3-A68 cells,
equine dermis (E. Derm) cells and equine brain microvascular endothelial cells. In addition,
inhibition of cell surface expression of MHC class I molecules in E. Derm cells drastically
reduced their susceptibility to EHV-1 infection. These results suggest that equine MHC class I
is a functional gD receptor that plays a pivotal role in EHV-1 entry into equine cells.
Introduction
Equine herpesvirus-1 (EHV-1), an alphaherpesvirus of
the family Herpesviridae with a worldwide distribution,
can cause respiratory disease, abortion and encephalo-
myelitis in horses. Although encephalomyelitis is
uncommon, outbreaks of neurologic EHV-1 have
caused great damage to the equine industry (Stierstor-
fer et al. 2002; Studdert et al. 2003; Kohn et al. 2006;
Heerkens 2009); still, neither vaccination nor effective
treatments are available for this disease. Following
airborne transmission, EHV-1 infects respiratory
epithelial cells and mononuclear leukocytes in the
local lymph nodes, resulting in leukocyte-associated
viremia. The virus then infects endothelial cells of
arteries and capillaries in the central nervous system
(CNS). Previous research has shown that the inﬂam-
mation following viral replication in the endothelial
cells triggers encephalomyelitis secondary to vasculitis,
thrombosis and ischemic damage of the CNS
(Edington et al. 1986; Whitwell & Blunden 1992;
Stierstorfer et al. 2002). However, the mechanisms
underlying EHV-1 endotheliotropism still need to be
elucidated.
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343Alphaherpesviruses, including herpes simplex virus
type 1 (HSV-1), HSV-2, varicella-zoster virus (VZV)
and pseudorabies virus (PRV), enter target cells
through a sequential multistep process. Following the
initial attachment of the viruses to the cell surface,
binding of viral glycoproteins to cell surface receptors
triggers fusion of the viral envelope with the cell
membrane, resulting in the release of viral capsid
(containing viral genome) into the cytoplasm. Various
alphaherpesvirus receptors have been previously iden-
tiﬁed, including a member of the tumor necrosis fac-
tor receptor family referred to as herpesvirus entry
mediator (HVEM or HveA); the members of the
immunoglobulin superfamily nectin-1 (HveC), nec-
tin-2 (HveB) and CD155 (HveD); 3-O-sulfated hep-
aran sulfate; paired immunoglobulin-like type 2
receptor a; nonmuscle myosin IIA; insulin-degrading
enzyme and myelin-associated glycoprotein (Mont-
gomery et al. 1996; Geraghty et al. 1998; Warner
et al. 1998; Shukla et al. 1999; Li et al. 2006; Satoh
et al. 2008; Arii et al. 2010; Suenaga et al. 2010). Chi-
nese hamster ovary (CHO)-K1 cells are naturally
resistant to HSV-1, HSV-2, PRV and VZV infection,
but these viruses can infect CHO-K1 cells transfected
with the corresponding receptor. In contrast, EHV-1
efﬁciently enters and replicates in CHO-K1 cells,
suggesting that EHV-1 utilizes a unique entry recep-
tor (Frampton et al. 2005).
EHV-1 attaches to cell surfaces using an interaction
between viral glycoprotein C (gC) and cell surface
heparan sulfate (Osterrieder 1999). Although the role
of gC is important for effective infection, it does not
trigger viral entry into cells. Entry of EHV-1 occurs
either by endocytosis or by direct membrane fusion
with the cell surface, depending on cell types and
possibly on viral strains (reviewed in Osterrieder &
Van de Walle 2010). Glycoprotein D (gD) of EHV-1
is known to be essential for EHV-1 entry into rabbit
kidney (RK13) and CHO-K1 cells (Frampton et al.
2005; Whalley et al. 2007). It has been shown that
aV integrin mediates entry of the EHV-1 strain
L11Dgp2 into both CHO-K1 cells and equine
peripheral blood mononuclear cells (PBMC) through
the interaction with gD, but does not facilitate EHV-
1 entry into equine vascular endothelial cells (Van de
Walle et al. 2008). The functional gD receptors that
mediate EHV-1 entry into equine vascular endothelial
cells remain uncertain.
Primary cultured equine brain microvascular endo-
thelial cells (EBMECs) are an appropriate in vitro
model for EHV-1 endotheliotropism studies (Hasebe
et al. 2006). In this paper, we identiﬁed an equine
major histocompatibility complex (MHC) class I
heavy chain gene that rendered NIH3T3 cells suscep-
tible to EHV-1 infection, from a cDNA library of
primary cultured EBMECs. Equine MHC class I
directly interacted with EHV-1 gD, a viral protein
known to be important for EHV-1 entry. Interest-
ingly, EHV-1 dependence on MHC class I for entry
was observed in equine cell types, but not in CHO-
K1, which is a nonequine cell line also susceptible to
EHV-1 infection. Collectively, these results suggest
that equine MHC class I acts as a gD receptor for
EHV-1 entry into equine cell types, including CNS
endothelial cells.
Results
Complementary DNA library screening
We ﬁrst examined the attachment of EHV-1 to
EBMECs, which are highly susceptible to EHV-1
infection, and to murine ﬁbroblast-derived NIH3T3
cells, which are considered resistant to EHV-1 infec-
tion. Viral attachment was detected in both EBMECs
and NIH3T3 cells by ﬂow cytometry (Fig. 1A). How-
ever, following infection of the cells with the green
ﬂuorescent protein (GFP)-expressing EHV-1 mutant
strain (Ab4-GFP), the GFP signal was observed in EB-
MECs, but not in NIH3T3 (Fig. 1B). These results
suggest that NIH3T3 cells are resistant to EHV-1
infection despite efﬁcient cell surface viral attachment.
We next screened an equine brain microvascular
endothelial cell cDNA library for sequences that ren-
dered NIH3T3 cells susceptible to EHV-1 infection.
In the ﬁrst round of screening, plasmids from one
group of 20 bacterial stocks from the cDNA library
made six cells in the monolayer susceptible to Ab4-
GFP infection. GFP-positive cells were entirely
absent in the monolayer transfected with mock plas-
mids. To increase the frequency of conversion, we
subdivided the bacterial stock showing the highest
conversion frequency into groups of 10 and then
repeated plasmid DNA transfection and screening.
After ﬁve rounds of division and screening, we
obtained the desired plasmid clone (pcDNA201-81-
13-71-68). DNA sequencing of pcDNA201-81-13-
71-68 revealed that a cDNA insert of 1587 bp
encoded an open reading frame (ORF) of 365 amino
acids (aa). A search of the GenBank⁄EMBL⁄DDBJ
databases showed that this protein product exhibited a
similarity of 91% with the equine MHC class I heavy
chain ECMHCA1 (GenBank⁄EMBL⁄DDBJ entry
X71809).
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344According to the classiﬁcation of equine MHC
class I genes reported by Holmes & Ellis (1999), the
deduced aa sequence belonged to group A of the class
I sequence; therefore, we designated the cloned
cDNA (GenBank⁄EMBL⁄DDBJ entry AB525079) as
A68. A68 was subcloned from pcDNA201-81-13-
71-68 into the expression plasmid, pIRES2-Ds
Red-Express2, and the resulting plasmid was desig-
nated as pA68-DsRed. After inoculation of Ab4-
GFP, NIH3T3 cells transfected with pA68-DsRed
displayed cytopathic effects (CPE) and GFP expres-
sion, whereas NIH3T3 cells transfected with control
plasmid, pluc-DsRed encoding luciferase, showed
neither CPE nor GFP expression (Fig. 1C). Nearly all
GFP-positive cells showed DsRed positivity by ﬂow
cytometry analysis, suggesting that EHV-1 infection
occurred only in NIH3T3 cells successfully transfect-
ed with pA68-DsRed (Fig. 1C).
Figure 1 Equine herpesvirus-1 (EHV-1) infection of NIH3T3 cells expressing equine major histocompatibility complex (MHC)
class I. (A) Flow cytometric detection of EHV-1 virions bound to the cell surface of equine brain microvascular endothelial cells
(EBMECs) (upper panel) and NIH3T3 cells (lower panel). EHV-1-treated (solid line) and mock-treated (dashed line) cells were
stained with an anti-EHV-1 antibody. (B) EBMECs and NIH3T3 cells were inoculated with Ab4-GFP at an MOI of 5 for 12 h.
EHV-1 infected cells were identiﬁed by observing green ﬂuorescent protein (GFP) signals under a ﬂuorescence microscope. Scale
bars: 100 lm. (C) NIH3T3 cells transiently transfected with pA68-DsRed, pB118-DsRed or pluc-DsRed were infected with
EHV-1 Ab4-GFP at an MOI of 5. The number of GFP- and DsRed-positive cells was analyzed simultaneously by ﬂow cytometry.
Scale bars: 100 lm. (D) The expression of equine MHC class I was analyzed by ﬂow cytometry using an anti-equine MHC class I
antibody PT85A. Numbers on plots indicate the percentage of cells in the designated gate.
MHC class I acts as a EHV-1gD receptor
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345Because A68 was assigned to the MHC class I
gene family, we evaluated whether other equine
MHC class I heavy chain genes enhanced susceptibil-
ity to EHV-1 infection. A cDNA encoding equine
MHC class I heavy chain that was 100% identical to
the Equine classical MHC class I allele 118 partial cds
(GenBank⁄EMBL⁄DDBJ entry AY176106) was iso-
lated from EHV-1-susceptible equine dermal ﬁbro-
blast (E. Derm) cells by reverse transcriptase PCR
(RT-PCR). Because the deduced aa sequence of the
isolated equine MHC class I heavy chain belonged to
group B of the MHC sequence (Holmes & Ellis
1999), we designated the cloned cDNA (Gen-
Bank⁄EMBL⁄DDBJ entry AB525080) as B118 and
constructed pB118-DsRed by cloning it into the
pIRES2-DsRed-Express2 expression vector. NIH3T3
cells transfected with pB118-DsRed also showed CPE
and GFP expression after inoculation with Ab4-GFP
(Fig. 1C). Flow cytometry using the anti-MHC class
I antibody PT85A, a monoclonal antibody that rec-
ognizes horse MHC class I but not mouse MHC class
I, conﬁrmed the cell surface expression of equine
MHC class I in NIH3T3 cells transfected with pA68-
DsRed or pB118-DsRed, but not in those transfected
with control plasmid (Fig. 1D). We also isolated
mouse MHC class I, H2K, and H2D from mouse
spleen cDNA and conﬁrmed that the over-expression
of murine MHC class I did not confer susceptibility
to EHV-1 infection (data not shown). These results
indicate that cell surface expression of equine MHC
class I renders NIH3T3 cells susceptible to EHV-1
infection.
Effect of equine MHC class I expression on
NIH3T3 cells
To further analyze the function of equine MHC class
I molecules in EHV-1 infection, we established an
NIH3T3-derived cell line that stably expresses A68
(3T3-A68). Anti-equine MHC class I monoclonal
antibodies PT85A (Isotype IgG2a), H58A (Isotype
IgG2a) and B5C (Isotype IgG2b) speciﬁcally reacted
with A68 on the cell surface of 3T3-A68 (Fig. 2A).
We attempted to neutralize viral infection by incubat-
ing cells with these anti-MHC class I antibodies.
After preincubation with the antibodies or the IgG
isotype controls, cells were exposed to Ab4-GFP.
Viral entry was evaluated by counting the number of
GFP-expressing cells using ﬂow cytometry. PT85A
treatment signiﬁcantly inhibited virus entry into 3T3-
A68 (inhibition of 59% compared to the mock treat-
ment), but H58A and B5C did not block viral entry
signiﬁcantly (Fig. 2B). We also investigated the neu-
tralizing activity of anti-MHC class I antibodies on
EBMECs. Expression of MHC class I on EBMECs
was conﬁrmed by ﬂow cytometry (Fig. S1 in Sup-
porting Information). PT85A and H58A prevented
EHV-1 entry into EBMECs (infection inhibition of
95% and 62%, respectively) (Fig. 2C). These results
suggest that equine MHC class I molecules are
involved in EHV-1 entry into both 3T3-A68 cells
and EBMECs.
We next examined the effects of cellular ATP
depletion on EHV-1 entry into 3T3-A68 cells. ATP
depletion is known to inhibit endocytosis, but has no
effect on herpesvirus entry by direct fusion of viral
envelopes with plasma membranes (Nicola et al.
2003). Previous studies have suggested that entry of
EHV-1 into CHO-K1 cells occurs via an endocytic
mechanism (Frampton et al. 2007; Van de Walle et al.
2008), whereas entry into RK13 cells occurs by direct
fusion at the cell surface (Frampton et al. 2007).
Therefore, we used CHO-K1 and RK13 cells as
positive and negative controls, respectively, for deter-
mining the effect of cellular ATP depletion on EHV-
1 entry. We also used E. Derm cells as a positive
control because EHV-1 entry into E. Derm cells was
reduced by ATP depletion (Hasebe et al. 2009). An
ATP depletion experiment was performed by using
the method described by Hasebe et al. (2009) with
minor modiﬁcations. To exclude the toxic inﬂuence
of ATP depletion on cell viability, the effect of ATP
depletion on EHV-1 entry was estimated by dividing
the number of infected cells obtained from the ATP
depletion media during viral infection (viral entry
step) by the number of infected cells obtained from
the ATP depletion media after viral infection (post-
viral entry step). ATP depletion during viral entry
reduced EHV-1 infection in 3T3-A68 as well as
CHO-K1 and E. Derm cells (Fig. 2D). In contrast,
EHV-1 infection was not inhibited in RK13 cells
(Fig. 2D). The observed decrease in cellular ATP lev-
els in each cell line (Fig. S2 in Supporting Informa-
tion) suggests that EHV-1 entry into 3T3-A68 cells
depends on cellular ATP, which is required for viral
cell entry via endocytosis.
We performed RT-PCR to conﬁrm EHV-1 gene
expression in 3T3-A68 cells using speciﬁc primer sets
for immediate early (IE), early (ICP0) and late (gB,
gD and gK) EHV-1 genes. At 4 h postinfection (p.i.),
all genes were detected in 3T3-A68 and E. Derm
cells, whereas no viral RNA was detected in
NIH3T3 cells (Fig. 2E). Because no PCR product
was detected in the samples without transcriptase,
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346ampliﬁed products were not derived from the viral
genomic DNA (data not shown). We also investigated
whether 3T3-A68 cells could support EHV-1 replica-
tion by evaluating the kinetics of viral growth. The
extracellular titers of 3T3-A68 and E. Derm cells
gradually increased with time (Fig. 2F). Conversely,
EHV-1-inoculated NIH3T3 cells yielded no infectious
progeny at 24 h p.i. (Fig. 2F). These results suggest that
Figure 2 Effect of equine major histocompatibility complex (MHC) class I expression on NIH3T3 cells. (A) Flow cytometric
detection of equine MHC class I expression on 3T3-A68 (upper panel) and NIH3T3 cells (lower panel) stained with anti-MHC
class I antibody PT85A (red), H58A (blue), B5C (orange) or isotype controls IgG2a and IgG2b (black and gray, respectively). (B
and C) Infectivity neutralizing assay. 3T3-A68 cells (B) and equine brain microvascular endothelial cells (EBMECs) (C) were
preincubated with 50 lg⁄mL of anti-MHC class I or control antibodies for 30 min and then infected with equine herpesvirus-1
(EHV-1) Ab4-GFP at an MOI of 5 in the presence of the antibody for 2 h at 37  C. After treatment with a low-pH citrate buffer
to inactivate extracellular virions, incubation was continued for a further 12 h. Green ﬂuorescent protein (GFP)-positive cells were
counted by ﬂow cytometry. Bars represent the means from three samples, and error bars show standard deviations. Statistical signif-
icance was determined by Student’s t-tests and is indicated by asterisks (**P < 0.01). (D) Effect of cellular ATP depletion on
EHV-1 entry into cells. RK13, 3T3-A68, CHO-K1 and E. Derm cells were treated with ATP depletion media during or postviral
entry. These cells were infected with Ab4-GFP, and GFP-positive cells were counted by ﬂow cytometry. The number of infected
cells treated with ATP depletion media postviral entry was deﬁned as one. The graphs show the mean and standard deviation of
three independent experiments. (E) Expression of viral RNAs in 3T3-A68, NIH3T3 and E. Derm cells. Cells were infected with
EHV-1 Ab4-GFP, and total RNA was extracted at 0 and 4 h postinfection (p.i.) Immediate early (IE), early (ICP0) and late (gB,
gD, gK) transcripts were detected by RT-PCR. GAPDH was used as an internal control. (F) Time course of viral growth in E.
Derm (white bars), 3T3-A68 (gray bars) and NIH3T3 (black bars) cells. Cells were infected to Ab4-GFP at an MOI of 5 for 1h
and washed with PBS to remove uninfected virus. The viral titer of each supernatant was determined by a plaque formation assay
on RK13 cells. Each bar represents the amount of cell-free virus as the mean of three independent samples. Error bars show stan-
dard deviations.
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347equine MHC class I molecules mediate EHV-1 entry
and subsequent replication in 3T3-A68 cells.
Involvement of EHV-1 gD on equine MHC class
I-mediated viral entry
Glycoprotein D (gD) of EHV-1 is known to be
important for EHV-1 entry into RK13 (Whalley et al.
2007) and CHO-K1 cells (Van de Walle et al. 2008).
To evaluate the role of gD on equine MHC class
I-mediated entry, we tested the ability of anti-gD
polyclonal antibody to block EHV-1 infection of
3T3-A68 cells. Anti-gD polyclonal antibody inhibited
EHV-1 entry in a dose-dependent manner (Fig. 3A).
We next generated a soluble gD-Ig fusion protein
consisting of the extracellular domain of EHV-1 gD
and the Fc segment of the human immunoglobulin
G1 (IgG1) and tested its ability to block EHV-1 infec-
tion of 3T3-A68 cells as previously described by Satoh
et al. (2008). gD-Ig also inhibited EHV-1 entry into
3T3-A68 cells in a dose-dependent manner, with con-
centrations higher than 30 ug⁄mL being effective at
blocking infection (Fig. 3B). Anti-gD antibody and
gD-Ig also inhibited EHV-1 entry into 3T3-B118
cells, a NIH3T3-derived cell line stably expressing the
other allele of equine MHC class I (data not shown).
These results suggest that EHV-1 gD is involved in
equine MHC class I-mediated EHV-1 entry.
To investigate the putative interaction between
equine MHC class I and EHV-1 gD, lysates of cells
expressing hemagglutinin (HA)-tagged A68 (A68-
HA) were incubated with gD-Ig fusion protein using
coupled magnetic beads. A68 was precipitated by
gD-Ig but not by the control-Ig (Fig. 4A). We also
conﬁrmed that EHV-1 gD was precipitated by the
soluble A68-Ig fusion protein (Fig. 4B). Next, we
analyzed the direct binding of gD to A68 expressed
on the cell surface, which induced binding of gD-Ig,
but not control-Ig, to cells (Fig. 4C). Similarly,
A68-Ig reacted with EHV-1 gD expressed on the cell
surface (Fig. 4D). Cell surface expression of A68 and
EHV-1 gD was conﬁrmed by staining with speciﬁc
antibodies (Fig. 4C,D). These results indicate that
EHV-1 gD acts as a ligand for equine MHC class I
molecules on the cell surface.
Anti-MHC class I antibodies block EHV-1 entry
into equine cells
We investigated the involvement of MHC class I mol-
ecules in EHV-1 entry into other equine cell types
that are susceptible to EHV-1 infection, such as E.
Derm cells and equine PBMC. Expression of MHC
class I on E. Derm cells and PBMC was conﬁrmed by
ﬂow cytometry using the same anti-MHC class I anti-
bodies used in Fig. 2B,C (Fig. S1 in Supporting Infor-
mation). After preincubation with these antibodies or
the IgG isotype controls, cells were exposed to Ab4-
GFP. PT85A and H58A treatment signiﬁcantly inhib-
ited virus entry into E. Derm cells (inhibition of 58%
and 30% compared to the mock treatment, respec-
tively) (Fig. 5A). PT85A and H58A also prevented
EHV-1 entry into PBMC (infection inhibition of 33%
and 65%, respectively) (Fig. 5B). On the other hand,
treatment with B5C did not lead to inhibition of
EHV-1 entry into these cells. These results suggest
that equine MHC class I molecules are involved in
EHV-1 entry into different types of equine cells.
MHC class I molecules play a pivotal role in
EHV-1 entry into E. Derm cells
As PT85A markedly prevented EHV-1 entry into E.
Derm cells (Fig. 5A), we postulated that EHV-1
enters equine cells mainly via a MHC class I-depen-
dent pathway. To test this hypothesis, we examined
Figure 3 Involvement of equine herpesvirus-1 (EHV-1) glyco-
protein D (gD) in equine major histocompatibility complex
(MHC) class I-mediated viral entry. (A) Inhibition of EHV-1
entry by anti-gD polyclonal antibody. EHV-1 Ab4-GFP at a
ﬁnal MOI of 5 was incubated with anti-gD polyclonal anti-
body (open circles) or control rabbit IgG (solid squares) for
30 min, and the virus–antibody mixture was added to 3T3-
A68 cells. After incubation for 2 h, extracellular virus was
inactivated by treatment with citrate buffer. Green ﬂuorescent
protein (GFP)-positive cells were counted by ﬂow cytometry.
(B) Inhibition of EHV-1 entry by gD-Ig fusion protein. 3T3-
A68 cells were incubated with gD-Ig (open circles) or con-
trol-Ig (solid squares) for 30 min and infected with the EHV-1
Ab4-GFP at an MOI of 5. After incubation for 2 h, extracel-
lular virus was inactivated by treatment with citrate buffer.
GFP-positive cells were counted by ﬂow cytometry. Error bars
represent standard deviations of three independent samples.
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348the effect of endogenous MHC class I gene knock-
down on EHV-1 infection of E. Derm cells using
lentiviral delivery of short hairpin RNAs (shRNAs).
The recombinant lentivirus would drive shRNA syn-
thesis under the control of the H1 promoter and
express monomeric red ﬂuorescent protein 1
(mRFP1) under the control of the cytomegalovirus
promoter, thereby enabling us to identify lentivirus
infected cells by mRFP1 gene expression (Fig. 6G,K).
A transduction efﬁciency higher than 95% was esti-
mated from mRFP1 expression.
We constructed recombinant viruses carrying
shRNA that targeted equine MHC class I heavy
chain mRNA. However, MHC class I expression was
not sufﬁciently reduced (data not shown), probably
due to MHC class I gene polymorphisms (Figueiredo
et al. 2006).
MHC class I molecules are composed of a single
membrane-spanning heavy chain paired with a solu-
ble protein b2-microglobulin (b2m). The cell surface
expression of MHC class I depends on the noncova-
lent binding of the heavy chain and b2m (Bjorkman
& Parham 1990). Figueiredo et al. (2006) found that
b2m-speciﬁc shRNA silenced MHC class I molecules
on the cell surface. Therefore, we designed two
shRNA constructs targeting equine b2m (designated
shb2m1 and shb2m2). Flow cytometric analysis indi-
cated that E. Derm cells transduced with b2m-speciﬁc
shRNAs showed silenced b2m expression and
reduced MHC class I cell surface expression com-
pared to nontreated cells or cells transduced with
luciferase-speciﬁc shRNA (shluc) (Fig. 6A).
Nontreated or shRNA-transduced E. Derm cells
were then infected with Ab4-GFP. Although there
were a few GFP-positive cells, almost all of the b2m-
speciﬁc shRNA-transduced E. Derm cells showed
neither CPE (Fig. 6F,G) nor GFP expression
(Fig. 6H). In contrast, nontreated (Fig. 6B–E) and
shluc-transduced (Fig. 6J–M) cells demonstrated both
CPE and GFP expression after EHV-1 infection,
indicating that these cells were still susceptible to
EHV-1 infection. The number of EHV-1 infected
Figure 4 Interaction of equine major histocompatibility complex (MHC) class I with equine herpesvirus-1 (EHV-1) glycoprotein
D (gD). (A, B) Immunoprecipitation assay. (A) Protein A beads coupled with gD-Ig or control-Ig were incubated with a lysate of
293T cells co-transfected with HA-tagged A68 and equine b2m expression plasmids. (B) Protein A beads coupled with A68-Ig or
control-Ig were incubated with a lysate of 293T cells transfected with the EHV-1 gD expression plasmid. Precipitated proteins
were separated by SDS-PAGE and subjected to immunoblotting (IB) using the antibodies indicated. Solid arrowhead, open arrow-
head and arrow indicate gD-Ig, A68-Ig and control Ig, respectively. (C, D) Binding assay of gD and A68. (C) A68 and equine
b2m co-transfected 293T cells (solid line) or mock vector transfected 293T cells (dashed lines) were incubated with anti-equine
MHC class I monoclonal antibody (left), gD-Ig (middle) or control-Ig (right). (D) 293T cells transfected with EHV-1 gD (dashed
lines) or mock vector (dashed lines) were incubated with anti-gD polyclonal antibody (left), A68-Ig (middle) or control-Ig (right).
Bound Ig fusion proteins were stained with phycoerythrin-conjugated anti-human IgG and analyzed by ﬂow cytometry.
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349cells was reduced in shb2m1- and shb2m2-transduced
E. Derm cells when compared to mock cells
(Fig. 6N). These results suggest that MHC class I is a
major determinant of susceptibility to EHV-1 infec-
tion in E. Derm cells.
MHC class I expression on CHO-K1 cells has no
role in EHV-1 infection
EHV-1 is able to infect CHO-K1 cells, which are nat-
urally resistant to HSV-1, HSV-2, PRV and VZV
entry. Therefore, we investigated whether MHC class
I is also involved in EHV-1 entry into CHO-K1 cells.
Anti-MHC class I antibody H58A and B5C reacted
with MHC class I on CHO-K1 (Fig. 7A); however,
these antibodies failed to block EHV-1 entry
(Fig. 7B). PT85A did not recognize Chinese hamster’s
MHC class I (Fig. 7A). We also conﬁrmed the inﬂu-
ence of b2m knockdown on CHO-K1 cells. The sur-
face expression of MHC class I was strongly reduced
by the transduction of shRNAs targeting Chinese
hamster’s b2m (Fig. 7C). The levels of EHV-1
infection in b2m-knockdown cells were comparable
to those in nontreated and shluc-transduced cells
Figure 5 Inhibition of equine herpesvirus-1 (EHV-1) entry
into equine cells with an anti-major histocompatibility com-
plex (MHC) class I antibody. (A) E. Derm and (B) equine
peripheral blood mononuclear cells were preincubated with
50 lg⁄mL of anti-MHC class I or control antibodies for
30 min and then infected with EHV-1 Ab4-GFP at an MOI
of 5 in the presence of the antibody for 2 h at 37  C. After
removing virus–antibody mixtures, cells were treated with a
low-pH citrate buffer to inactivate extracellular virions. Incu-
bation was continued for a further 12 h. Green ﬂuorescent
protein (GFP)-positive cells were counted by ﬂow cytometry.
Bars represent the means from three samples, and error bars
show standard deviations. Statistical signiﬁcance was deter-
mined by Student’s t-tests and is indicated by asterisks
(*P < 0.05, **P < 0.01).
(A)
(B) (C) (D) (E)
(F) (G) (H) (I)
(J) (K) (L) (M)
(N)
Figure 6 Knock-down of the cell surface expression of major histocompatibility complex (MHC) class I. E. Derm cells were
infected with recombinant lentiviruses carrying both shRNA and mRFP1 expression cassettes. E. Derm cells were transduced with
equine b2m-speciﬁc shRNA (shb2m1 and shb2m2) or luciferase-speciﬁc shRNA (shluc). (A) Flow cytometric analysis of the cell
surface expression of MHC class I. Cells transduced with shRNAs (solid lines) or nontreated E. Derm cells (dashed line) were
stained with anti-MHC class I antibody PT85A. (B–M) Effect of shRNA transduction on the susceptibility of E. Derm cells to
equine herpesvirus-1 (EHV-1). Cells were infected with Ab4-GFP at an MOI of 1 for 24 h. Transduction of shRNA lentiviral
vectors was conﬁrmed by mRFP1 expression and infection of Ab4-GFP was conﬁrmed by green ﬂuorescent protein (GFP) expres-
sion under a ﬂuorescence microscope. Scale bars: 100 lm. (N) After infection with Ab4-GFP, GFP-positive cells were counted by
ﬂow cytometry. The bars represent the means from three samples, and error bars show standard deviations. Statistical signiﬁcance
was analyzed by Student’s t-test and is indicated by an asterisk (**P < 0.01).
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350(Fig. 7D). These data indicate that EHV-1 does not
depend on MHC class I for entry into CHO-K1 cells.
Discussion
In this study, the surface expression of equine MHC
class I heavy chains cloned from EBMECs or E.
Derm cells rendered mouse NIH3T3 cells susceptible
to EHV-1 infection, with EHV-1 entry and subse-
quent replication in these cells depending on the
expression of MHC class I. Pretreatment of equine
cells, including primary cultured EBMECs and
PBMC which are important targets of EHV-1 in vivo,
with an anti-equine MHC class I monoclonal anti-
body inhibited EHV-1 entry. Moreover, the suscepti-
bility of E. Derm cells to EHV-1 infection was
markedly inhibited by b2m gene knockdown, which
subsequently reduced the surface expression of all
MHC class I molecules. These results suggest that
equine MHC class I plays an important role in EHV-1
entry into equine cells.
A mechanism of entry for EHV-1 was recently
reported by another group (Kurtz et al. 2010); how-
ever, they demonstrated the involvement of MHC
class I only in a case of EHV-1 entry into a mouse
melanoma cell line with exogenously overexpressed
MHC class I. Therefore, our study is the ﬁrst to show
that equine MHC class I molecules actually mediate
EHV-1 entry into equine cell types, which are natu-
rally susceptible to EHV-1 infection.
Alphaherpesviruses entry into target cells occurs a
cascade of direct interactions between viral glycopro-
teins and receptors (Spear 2004; Heldwein & Krum-
menacher 2008). Receptors for HSV-1 on the host
cell surface bind to HSV-1 gD, triggering viral entry
into cells (Whitbeck et al. 1997; Krummenacher et al.
1998; Shukla et al. 1999). Blocking the interaction
between entry receptors and gD inhibits HSV-1 entry
and infection (Whitbeck et al. 1997; Geraghty et al.
1998; Shukla et al. 1999). A previous study showing
the involvement of MHC class I in EHV-1 entry did
not identify the viral protein that acts as a ligand for
MHC class I (Kurtz et al. 2010). In this study, we
demonstrated that EHV-1 gD interacts with equine
MHC class I and that viral entry into 3T3-A68 cells
was inhibited by treatment with anti-gD antibody
and a soluble form of gD. These results suggest that
equine MHC class I acts as an entry receptor for
EHV-1 by binding to EHV-1 gD.
Our data showed that only a fraction of NIH3T3
cells expressing MHC class I was infected with EHV-
1. This ﬁnding suggests that the cell surface expres-
sion of MHC class I is not the sole determinant for
the susceptibility of NIH3T3 cells to EHV-1. Cellular
factors other than equine MHC class I might be
required for establishing highly efﬁcient infection of
NIH3T3 cells with EHV-1.
In this study, anti-MHC class I antibodies showed
variable inhibition effects on EHV-1 infection in dif-
ferent cell types (Figs 2B,C, 5A,B). One possible
Figure 7 Major histocompatibility complex (MHC) class
I-independent infection of CHO-K1 cells by equine herpesvi-
rus-1 (EHV-1). (A) Flow cytometric detection of hamster
MHC class I expression on CHO-K1 cells stained with anti-
MHC class I antibody PT85A (red), H58A (blue), B5C
(orange) or isotype controls IgG2a and IgG2b (black and gray,
respectively). (B) CHO-K1 cells were preincubated with
50 lg⁄mL of anti-MHC class I or control antibodies for
30 min and then infected with the EHV-1 Ab4-GFP at an
MOI of 5 in the presence of antibody for 2 h at 37  C. After
removing virus–antibody mixtures, cells were treated with a
low-pH citrate buffer to inactivate extracellular virions. Incu-
bation was continued for a further 12 h. Green ﬂuorescent
protein (GFP)-positive cells were counted by ﬂow cytometry.
Bars represent means from three samples, and error bars show
standard deviations. (C, D) Knock-down of the cell surface
expression of MHC class I by transduction of Chinese ham-
ster’s b2m-speciﬁc shRNA (shb2m3 and shb2m4). (C) Flow
cytometric analysis of the cell surface expression of MHC class
I. Cells expressing shb2m4 (solid line) and no shRNA (dashed
line) were stained with anti-MHC class I antibody H58A. (D)
Cells expressing shRNA were infected with the EHV-1 Ab4-
GFP at an MOI of 1 for 24 h. GFP-positive cells were
counted by ﬂow cytometry. Bars represent means from three
samples, and error bars show standard deviations.
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351explanation for this variability is that the extent of
inhibition of EHV-1 entry by anti-MHC class I anti-
bodies may be inﬂuenced by the number and⁄or
diversity of MHC class I molecules expressed on each
cell type. As MHC molecules are polymorphic, the
degree of monoclonal antibody reactivity may vary
among MHC class I molecules encoded by different
loci.
Equine MHC class I genes are located on chromo-
some 20 (Ansari et al. 1988; Gustafson et al. 2003). It
is still unclear how many class I genes exist within
the horse genome, but the presence of up to 33
MHC class I genes and⁄or pseudo genes is indicated
by restriction fragment length polymorphisms of the
equine genome (Alexander et al. 1987). Moreover, 15
MHC class I loci were identiﬁed and sequenced from
bacterial artiﬁcial chromosome clones containing
homozygous MHC horse genes, and seven of these
loci were transcribed into the mRNA in adult lym-
phocytes by RT-PCR (Tallmadge et al. 2005).
Although our study showed that at least two equine
MHC class I heavy chains, A68 and B118, confer sus-
ceptibility to EHV-1 infection, further studies are
needed to determine whether all equine MHC class I
molecules are involved in EHV-1 entry.
Although this study demonstrates the role of
equine MHC class I in EHV-1 entry into equine
cells, the distribution of MHC class I itself may not
correlate directly with EHV-1 tissue tropism, as virtu-
ally all cell types can express MHC class I molecules
(David-Watine et al. 1990). Therefore, host factors
other than MHC class I may be involved in the
observed EHV-1 tropism.
Recently, aV integrins were shown to be impor-
tant for EHV-1 entry into CHO-K1 cells but not
endothelial cells collected from the carotid arteries of
horses, suggesting the existence of different pathways
of EHV-1 entry in these cells (Van de Walle et al.
2008). Here, we demonstrated that MHC class I par-
ticipates in EHV-1 entry into equine cells; however,
pretreatment with anti-MHC class I antibody and the
reduction of cell surface MHC class I expression by
b2m knockdown did not alter the susceptibility of
CHO-K1 cells to EHV-1. These data indicate that
EHV-1 relies on different pathways for entry into dif-
ferent types of host cells.
The mouse intranasal infection model has many
similarities to natural infection in horses. Intranasal
infection of adult mice causes local viral replication in
the respiratory mucosa, with formation of intranuclear
inclusions and subsequent rhinopneumonitis (Awan
et al. 1990; Inazu et al. 1993; Bartels et al. 1998).
However, this model does not develop encephalomy-
elitis, a characteristic of viral infection in CNS endo-
thelial cells. Our results suggest that EHV-1 is
unlikely to utilize mouse MHC class I as a factor for
entry into mouse cells because the NIH3T3 cells used
in this study (which are not naturally susceptible to
EHV-1 infection) expressed mouse MHC class I mol-
ecules (haplotype H2
q) on their surface (Seliger et al.
1998; Herrmann et al. 2004). Interestingly, in contrast
to the EBMECs that expressed equine MHC class I
and were thus susceptible to EHV-1 infection, mouse
brain microvascular endothelial cells are completely
resistant to EHV-1 infection and are not susceptible
to viral entry (Hasebe et al. 2006). Therefore, the dif-
ferences between the host factors underlying EHV-1
entry in equine and mouse cells may contribute to
the difference in EHV-1 pathogenicity between the
horse and the mouse model.
In summary, we demonstrated that equine MHC
class I molecule acts as a functional gD receptor for
EHV-1 entry and infection, which contributes to the
understanding of the molecular mechanisms of EHV-
1 entry into cells (Table S1 in Supporting Informa-
tion). In recent years, outbreaks of the neurologic
EHV-1 have occurred at various equine facilities
worldwide. An effective approach to therapy and pre-
vention is still under investigation. Transgenic mice
expressing equine MHC class I on their endothelial
cells, already under development, might provide a
suitable model for the study of EHV-1 pathogenesis,
aiding in the investigation of novel vaccines and drugs
for EHV-1 infection.
Experimental procedures
Cells and viruses
NIH3T3 and 293T cells were cultured in Dulbecco’s modiﬁed
Eagle medium (DMEM) containing 10% fetal bovine serum
(FBS). E. Derm cells (CCL-57; ATCC, Manassas, VA, USA)
were cultured in DMEM supplemented with 10% FBS and
0.1 mM nonessential amino acids. RK13 cells were cultured in
Eagle’s minimum essential medium (MEM) containing 10%
FBS. CHO-K1 cells were cultured in DMEM⁄F-12 contain-
ing 10% FBS. PBMC were isolated from equine blood by
density gradient centrifugation over Histopaque 1077 (Sigma,
St Louis, MO, USA) and maintained in RPMI 1640 medium
supplemented with 10% FBS, 50 lM 2-mercaptoethanol and
10 lg⁄mL gentamicin. Primary EBMECs were isolated from a
horse brain as described previously (Hasebe et al. 2006) and
were cultured in Medium 199 Earl’s (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% FBS and 10 lg⁄mL genta-
micin. All cells were maintained at 37  Ci n5 %C O 2. The
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352EHV-1 mutant Ab4-GFP contains a GFP expression cassette
between ORF 62 and ORF 63 (Ibrahim el et al. 2004). Stock
viruses were cultured in E. Derm cells and titrated by plaque
formation assay on RK13 cells.
Plasmids
The pIRES2-DsRed-Express2 (Clontech Laboratories, Palo
Alto, CA, USA) is a bicistronic expression vector containing
the internal ribosome entry site 2 (IRES2) between the multiple
cloning site and the red ﬂuorescent marker protein DsRed-
Express2 coding region. The pCXSN vector was generated by
removing the c-myc epitope tag from pCMV-Myc (Clontech
Laboratories) and replacing the multiple cloning site with Xho I,
Sal I and Not I. The self-inactivating (SIN) lentiviral vector
constructs (CSII-CMV-MCS-IRES2-Bsd and CS-RfA-CMV-
mRFP1), entry vector (pENTR4-H1), packaging construct
(pCAG-HIVgp) and the VSV-G- and Rev-expressing construct
(pCMV-VSV-G-RSV-Rev) were kindly provided by Dr Mi-
yoshi (RIKEN BioResource Center, Ibaraki, Japan). To gener-
ate the Ig fusion proteins, a pME18S expression vector
containing a mouse CD150 leader segment at the N terminus
and Fc segment of human IgG1 at C terminus (Satoh et al.
2008) was kindly provided by Dr Arase (Osaka University,
Osaka, Japan). To construct the expression plasmids, cDNA
fragments of equine MHC class I B118 and b2m and of H2K
and H2D were respectively ampliﬁed from the total RNA of E.
Derm cells and of C57BL⁄6 mice spleen by RT-PCR. cDNA
fragments of EHV-1 gD were ampliﬁed from the genome of
EHV-1 Ab4-GFP virus by PCR. A68 expression vectors con-
taining HA epitope tag, pCXSN-A68-HA, were constructed
using pCXSN-A68 as templates. PCR primers used in this
study are listed in Table S2 in Supporting Information.
Complementary DNA isolation
A unidirectional EBMECs cDNA library cloned into the Eco
RI-Xho I site of the pcDNA 3.1 (+) vector (Invitrogen) in
Escherichia coli DH10B was plated onto two hundred 150-mm
LB agar plates containing ampicillin (100 lg⁄mL). Colonies
were pooled by scraping and frozen in glycerol. Samples of
each stock were combined into groups of 20 and cultured in
LB broth with 100 lg⁄mL ampicillin at 37  C. Plasmid DNA
was prepared using a QIAprep Spin Miniprep kit (Qiagen,
Valencia, CA, USA). NIH3T3 cells plated in six-well plates
were transfected with plasmid DNA from each pool by using
Lipofectamine 2000 (Invitrogen). Cells transfected with the
GFP-expressing plasmid pEGFP-N1 (Clontech Laboratories)
or with pcDNA 3.1 (+) were used as controls. Thirty hours
after transfection, cells were infected with Ab4-GFP at a
multiplicity of infection (MOI) of 5. At 24 h p.i., we deter-
mined the susceptibility of cells to Ab4-GFP by counting the
number of GFP-expressing cells under an inverted ﬂuores-
cence microscope (IX70; Olympus, Tokyo, Japan). The stock
that yielded the largest number of infected cells was divided
into one hundred pools. This process of subdivision and
screening was repeated to obtain a single clone that yielded a
plasmid with the desired phenotype.
Establishment of an equine MHC class
I-expressing cell line
To obtain a cell line stably expressing the equine MHC class I
heavy chain gene, we used an HIV-1-based lentiviral vector
pseudotyped with the vesicular stomatitis virus G glycoprotein
(VSV-G) (Miyoshi et al. 1998). Brieﬂy, an MHC class I heavy
chain gene was cloned into the SIN lentiviral vector con-
struct, CSII-CMV-MCS-IRES2-Bsd. A recombinant lentivirus
vector was generated by transient transfection of 293T cells
with a combination of the SIN lentiviral vector construct,
pCAG-HIVgp and pCMV-VSV-G-RSV-Rev. The superna-
tant containing lentivirus vector was collected after incubation
of the cells at 37  C for 48 h. The A68 or B118-expressing
NIH3T3 cell lines (3T3-A68 and 3T3-B118) were established
by infecting NIH3T3 cells with each lentiviral vector and
cultured in the presence of 10 lg⁄mL blasticidin S HCl (Invi-
trogen).
Flow cytometry
Cells were detached with cell dissociation buffer (Invitrogen)
and washed with phosphate-buffered saline (PBS) containing
2% bovine serum albumin. Cells were stained with the anti-
MHC class I monoclonal antibody PT85A, H58A, B5C
(VMRD, Pullman, WA, USA) or anti-gD polyclonal antibody
(generated in our laboratory) at 4  C for 30 min. Mouse
IgG2a (BD Biosciences, San Jose, CA, USA), IgG2b and rab-
bit IgG (Beckman Coulter, Fullerton, CA, USA) were used as
controls. Cells were stained with an Alexa Fluor 488-conju-
gated anti-mouse IgG antibody (Invitrogen), allophycocyanin
(APC)-conjugated anti-mouse IgG or APC-conjugated anti-
rabbit IgG (Beckman Coulter) at 4  C for 30 min. Flow cyto-
metric analysis was performed using a FACS Canto system
(BD Biosciences), and the data collected were analyzed using
FLOWJO software (Tree Star, Ashland, OR, USA).
Generation of Ig fusion protein
The expression vectors pME18S-A68-IgG Fc and pME18S-
gD-IgG Fc were constructed by subcloning the extracellular
domain of gD and A68 into pME18S expression vectors. Ig
fusion proteins were expressed using the FreeStyle 293 expres-
sion system (Invitrogen) as described by the manufacturer.
Brieﬂy, 293F cells were transfected with pME18S-A68-IgG Fc
and pCXSN-equine b2m (for A68-Ig expression) or pME18S-
gD-IgG Fc (for gD-Ig expression) using 293fectin (Invitrogen).
Secreted Ig fusion proteins were puriﬁed on HiTrap rProtein
A FF column (GE Healthcare, Buckinghamshire, UK) and
buffer exchanged into PBS using an Amicon Ultra-15 centri-
fugal ﬁlter unit with an Ultracel-10 membrane (Millipore,
Bedford, MA, USA).
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353Immunoprecipitation assay
293T cells were transfected with gD expression plasmid, or
with HA-tagged A68 and equine b2m expression plasmids, to
obtain a high expression of A68 using 293fectin. Cells were
lysed in a lysis buffer [10 mM Tris–HCl (pH 7.5), 0.5% Brij
98, 150 mM NaCl] supplemented with complete protease
inhibitor cocktail (Roche, Basel, Switzerland). Lysed proteins
were incubated with Dynabeads Protein A (Invitrogen) for 1 h
at 4  C after coating with Ig fusion protein. Precipitated pro-
tein complexes were eluted with 0.1 M citrate buffer (pH 3.0)
and fractionated by SDS-PAGE. Proteins were transferred onto
Immobilon-P transfer membranes (Millipore) and detected
with anti-gD polyclonal antibody, anti-HA monoclonal anti-
body (Sigma) or anti-human IgG antibody (Jackson Immuno-
research, West Grove, PA, USA).
Binding assay
To detect virions attached to the cell surface, cells were
detached and incubated with Ab4-GFP at an MOI of 20. After
incubation for 1 h at 4  C, unbound virus was washed out
with PBS, stained with an anti-EHV-1 polyclonal antibody
(a gift from Dr Kirisawa, Rakuno Gakuen University, Hokkai-
do, Japan) and analyzed by ﬂow cytometry.
To assess Ig fusion protein binding, cells were detached and
incubated with 5 lg of Ig fusion protein at 4  C for 30 min.
Puriﬁed human IgG (Invitrogen) was used as a control Ig pro-
tein. Binding of the Ig fusion proteins was detected by phyco-
erythrin (PE)-conjugated anti-human IgG antibody (Beckman
Coulter) and analyzed by ﬂow cytometry.
ATP depletion assay
For samples depleted of cellular ATP during viral entry, cells
were preincubated in ATP depletion media composed of
glucose-free, FBS-free DMEM (Invitrogen) with 10 mM
2-deoxyglucose (Sigma) and 10 mM sodium azide (Sigma) for
30 min, and infected with Ab4-GFP at an MOI of 5 (RK13
and E. Derm) or 20 (3T3-A68 and CHO-K1) for 1 h in ATP
depletion media. After EHV-1 infection, cells were treated
with 0.1 M citrate buffer (pH 3.0) to inactivate remaining
viruses on the cell surface. The media were replaced with reg-
ular culture media and cells were cultured for 12 h at 37  C.
For samples depleted of ATP after postentry, cells were
infected with Ab4-GFP in FBS-free DMEM. After viral infec-
tion, cells were incubated in ATP depletion media for 1.5 h,
and then the media were replaced with regular culture media.
At 12 h p.i., GFP-positive cells were counted by ﬂow cytome-
try. Cellular ATP levels of each cell line treated or untreated
with the 2-deoxyglucose and sodium azide were measured
using the CellTiter-Glo luminescent cell viability assay (Pro-
mega, Madison, WI, USA) according to the manufacturer’s
instructions.
Detection of immediate early, early and late EHV-
1 mRNA expression
Cells were infected with Ab4-GFP at an MOI of 5. After
washing cells with PBS, total RNA was extracted at 0 h p.i.
(immediately after seeding the virus) and 4 h p.i. with TRIzol
reagent (Invitrogen). After treatment with ampliﬁcation-grade
DNase I (Invitrogen), RT-PCR was performed with primers
speciﬁc for EHV-1 immediate early (IE), early (ICP0) and late
(gB, gD, gK) genes, using the method described by Hasebe
et al. (2006).
Viral growth analysis
Cells were infected with Ab4-GFP at an MOI of 5. After
incubation at 37  C for 1 h to allow viral attachment, cells
were washed three times with PBS and re-fed with growth
media. At 1 h p.i. (immediately after the PBS wash), 8 and
24 h p.i., the supernatants were collected. The viral titer was
determined by plaque formation on RK13 cells.
Infectivity neutralization assay
For neutralization of viral gD, EHV-1 Ab4-GFP at an MOI of
5 were incubated with anti-gD polyclonal antibody or control
rabbit IgG for 30 min at 37  C, and the virus–antibody
mixture was added to the cells. After incubation for 2 h, extra-
cellular virus was inactivated by treatment with 0.1 M citrate
buffer (pH 3.0). The cells were maintained in fresh
growth medium for further 12 h p.i. Viral entry was assessed
by counting the number of GFP-positive cells using ﬂow
cytometry.
For competition of viral gD, 3T3-A68 cells were incubated
with gD-Ig fusion protein for 30 min at 37  C, followed by
infected 3T3-A68 cells for 2 h. Viral entry was evaluated as
described above.
For examination of the effects of anti-MHC class I antibod-
ies, cells were incubated with 50 lg⁄mL of antibodies for
30 min at 37  C. The cells were infected with Ab4-GFP virus
at an MOI of 5 for 2 h at 37  C. Viral entry was evaluated as
described above.
Lentiviral vector expressing shRNA
Lentiviruses carrying shRNA were generated using the method
described by Katayama et al. (2004). We designed shRNA
constructs, shb2m1 and shb2m2, that were speciﬁc for the
equine b2m sequence (GenBank accession number: X69083),
and shb2m3 and shb2m4 that were speciﬁc for Chinese ham-
ster b2m sequence (GenBank accession number: X57112). We
also generated shRNAs against luciferase (shluc) as a control
(Ui-Tei et al. 2004). Brieﬂy, the entry vectors pENTR4-H1-
shRNA were constructed by inverse PCR using the
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354pENTR4-H1 and synthetic primers (listed in Table S2 in Sup-
porting Information). Each entry vector was incubated with
the CS-RfA-CMV-mRFP1 vector in the presence of Gateway
LR Clonase (Invitrogen) for plasmid recombination. The
Clonase-recombinant SIN vector constructs, CS-H1-shRNA-
mRFP1, were transfected into 293T cells with the Lenti-X
HT packaging system (Clontech Laboratories).
b2-Microglobulin knockdown
Supernatants containing each lentivirus were applied to E.
Derm or CHO-K1 cells. Transduction of shRNA into cells
was conﬁrmed by mRFP1 expression. The effect of shRNA
knockdown was evaluated from the decreased level of
MHC class I heavy chain expression using ﬂow cytometry.
Cells expressing shRNA were infected with Ab4-GFP at an
MOI of 1 for 24 h. Fluorescence signals of mRFP1 and
GFP were observed under an inverted ﬂuorescence micro-
scope, and images were processed using DP manager soft-
ware (Olympus). GFP-positive cells were counted by ﬂow
cytometry.
Statistical analysis
Statistically signiﬁcant differences were determined by Stu-
dent’s t-tests. Results are presented as arithmetic means, and
bars represent standard deviations.
Accession numbers
The reported nucleotide sequence data are available in the
DDBJ⁄EMBL⁄GenBank databases under accession numbers
AB525079 (A68) and AB525080 (B118).
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